@FierceMedDev: UPDATED with interview: FDA approves Actavis intrauterine device to prevent pregnancy. Article | Follow @FierceMedDev
@VarunSaxena2: ICYMI yesterday: Boston Sci to acquire Endo's men's health devices for $1.6B. Story | Follow @VarunSaxena2
> Stanford University has licensed a cardiac atrial fibrillation device technology to Actuated Cardio Engineering, a spinoff of Actuated Medical. More
> Rock Health has invested an undisclosed sum in Chrono Therapeutics, a smoking cessation startup that got a $32 million Series A round last June. Release
> The IRay Radiotherapy from Oraya Therapeutics has received a CE mark extension to treat choroidal metastases, a cancer in the eye. This expands upon its prior approval for wet, age-related macular degeneration. More
Biotech News
@FierceBiotech: Bullish ex-Elan chief plots a $43M buy-in for upstart Serenus. Article | Follow @FierceBiotech
@JohnCFierce: Remember when the NVCA wailed over the unsustainable VC model in biotech, the FDA's fossilized review process? Ah, the old days... in 2012. | Follow @JohnCFierce
@DamianFierce: German Merck refers to itself as "Merck KGaA, Darmstadt, Germany" on every reference. We get it. You're German. More | Follow @DamianFierce
> Boehringer takes pole position with its 'breakthrough' anti-anticoagulant. Article
> Ambitious cancer R&D plans may explain Merck KGaA cutbacks. Item
> J&J picks the inaugural class for its Bay Area biotech incubator. Report
Pharma News
@FiercePharma: IYCMI yesterday: Medicare urged to crack down on antipsychotic scripts for dementia sufferers. Report | Follow @FiercePharma
@EricPFierce: FDA unloads another 14 observations on Hospira Vizag India plant, further delaying its opening. More from FiercePharmaManufacturing | Follow @EricPFierce
@CarlyHFierce: To avoid becoming deal bait, Mylan CEO may have to make another big buy. News | Follow @CarlyHFierce
> Novartis CEO: We can rebuild our good name after 'reputational hit' in Japan. Story
> Genentech's cancer drug supply switch costs more, delays treatment, survey finds. Article
> Gilead's hep C combo Harvoni wins NICE blessing at $58K price. Item
Biotech Research News
> Canadian researchers study a new mechanism of action for cancer metastasis. More
> Scripps investigators ID a key player in disarming chemotherapy. Report
> Glioblastoma project IDs a new approach to brain cancer and understanding EGFR. Article
> Researchers add insights to IL-37's anti-inflammatory potential. More
> Mount Sinai preclinical program flags a potential drug strategy for MS. Story
Pharma Manufacturing News
> Hospitals say Roche supply chain move is affecting patient care. Item
> Pfizer shuttering vitamin C plant in California, 70 workers out of jobs. Report
> Hospira's new India plant again faulted by the FDA. Story
> Companies strike trans-Pacific manufacturing and development agreement. More
> G&W Laboratories buying Teva plant after picking up one from Actavis. Article
Pharma Asia News
> Sun Pharma buys GSK's Tasmania opiates business to expand pain offerings. More
> Gilead moves from Japan to India lining up hep C, HIV licensing deals. Story
> Singapore's TauRx notes Alzheimer's candidate journal publication, but buzz eludes. Article
> Takeda confirms eyeing opportunities in India, elsewhere, in vaccine space. News
> Deadly flu outbreak in Hong Kong gathers pace, prompting vaccination push. More